Jan Ohrstrom is assuming the role of chief executive in addition to his current position as board chairman of the French biotech, Biom’up SA. Dr Ohrstrom is a medical doctor who has senior management experience with several companies, including Novo Nordisk, ZymoGenetics, ProFibrix and The Medicines Company. The present CEO, Etienne Binant, is leaving Biom’up to pursue other business opportunities, the company said. Biom’up develops and commercialises haemostatic products based on biopolymers for surgery. Its lead product is marketed in Europe and the US.
Biom’up announced the appointment on 31 May 2019.
Copyright 2019 Evernow Publishing Ltd